The vitamin D-binding protein (DBP) occupies a key node in the regulation of the vitamin D system. Being the main plasma carrier of vitamin D metabolites, it regulates their stability and bioavailability. However, DBP is also a multifunctional protein with roles in the organism’s actin scavenging system and immunomodulation. All these activities may affect multiple sclerosis (MS) pathophysiology. DBP can be measured in blood and cerebrospinal fluid, body fluids that have been investigated as sources of accessible biomarkers of MS. Yet, available data on DBP expression and function in MS are scattered and somewhat controversial. Aims of this review are to summarize current evidence from studies on DBP in MS patients, to discuss possible shortcomings and to highlight key points that need to be addressed to gain deeper insight into the role of DBP in MS.
SintzelMBRamettaMRederAT.Vitamin D and multiple sclerosis: A comprehensive review. Neurol Ther2018; 7: 59–85.
2.
ShoemakerTJMowryEM.A review of vitamin D supplementation as disease-modifying therapy. Mult Scler2018; 24: 6–11.
3.
DelangheJRSpeeckaertRSpeeckaertMM.Behind the scenes of vitamin D binding protein: More than vitamin D binding. Best Pract Res Clin Endocrinol Metab2015; 29: 773–786.
4.
SpeeckaertMHuangGDelangheJRet al. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta2006; 372: 33–42.
5.
ChunRF.New perspectives on the vitamin D binding protein. Cell Biochem Funct2012; 30: 445–456.
6.
MollgardKDziegielewskaKMSaundersNRet al. Synthesis and localization of plasma proteins in the developing human brain. Integrity of the fetal blood-brain barrier to endogenous proteins of hepatic origin. Dev Biol1988; 128: 207–221.
7.
YangMQinZZhuYet al. Vitamin D-binding protein in cerebrospinal fluid is associated with multiple sclerosis progression. Mol Neurobiol2013; 47: 946–956.
8.
VerbovenCBogaertsIWaelkensEet al. Actin-DBP: The perfect structural fit?Acta Crystallogr D Biol Crystallogr2003; 59: 263–273.
9.
MeierUGressnerOLammertFet al. Gc-globulin: Roles in response to injury. Clin Chem2006; 52: 1247–1253.
10.
HeadJFSwamyNRayR.Crystal structure of the complex between actin and human vitamin D-binding protein at 2.5 A resolution. Biochemistry2002; 41: 9015–9020.
11.
OtterbeinLRCosioCGraceffaPet al. Crystal structures of the vitamin D-binding protein and its complex with actin: Structural basis of the actin-scavenger system. Proc Natl Acad Sci U S A2002; 99: 8003–8008.
12.
VerbovenCRabijnsADe MaeyerMet al. A structural basis for the unique binding features of the human vitamin D-binding protein. Nat Struct Biol2002; 9: 131–136.
13.
SwamyNHeadJFWeitzDet al. Biochemical and preliminary crystallographic characterization of the vitamin D sterol- and actin-binding by human vitamin D-binding protein. Arch Biochem Biophys2002; 402: 14–23.
14.
BouillonRXiangDZConventsRet al. Polyunsaturated fatty acids decrease the apparent affinity of vitamin D metabolites for human vitamin D-binding protein. J Steroid Biochem Mol Biol1992; 42: 855–861.
15.
CarlssonMNilssonIBrudinLet al. Erythrocyte fatty acid composition does not influence levels of free, bioavailable, and total 25-hydroxy vitamin D. Scand J Clin Lab Invest2017; 77: 45–52.
16.
CarterGDPhinneyKW.Assessing vitamin D status: Time for a rethink?Clin Chem2014; 60: 809–811.
17.
BikleDDMalmstroemSSchwartzJ.Current controversies: Are free vitamin metabolite levels a more accurate assessment of vitamin D status than total levels?Endocrinol Metab Clin North Am2017; 46: 901–918.
18.
HerrmannMFarrellCLPuscedduIet al. Assessment of vitamin D status—A changing landscape. Clin Chem Lab Med2017; 55: 3–26.
19.
ChunRFPeercyBEOrwollESet al. Vitamin D and DBP: The free hormone hypothesis revisited. J Steroid Biochem Mol Biol2014; 144(Pt A): 132–137.
20.
MendelCM.The free hormone hypothesis: A physiologically based mathematical model. Endocr Rev1989; 10: 232–274.
21.
OlerodGMattsson HultenLHammarstenOet al. The variation in free 25-hydroxy vitamin D and vitamin D binding protein with season and vitamin D status. Endocr Connect2017; 6: 111–120.
22.
DaveyRX.Vitamin D-binding protein as it is understood in 2016: Is it a critical key with which to help to solve the calcitriol conundrum?Ann Clin Biochem2017; 54: 199–208.
23.
AhnJYuKStolzenberg-SolomonRet al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet2010; 19: 2739–2745.
24.
WangTJZhangFRichardsJBet al. Common genetic determinants of vitamin D insufficiency: A genome-wide association study. Lancet2010; 376: 180–188.
25.
JolliffeDAWaltonRTGriffithsCJet al. Single nucleotide polymorphisms in the vitamin D pathway associating with circulating concentrations of vitamin D metabolites and non-skeletal health outcomes: Review of genetic association studies. J Steroid Biochem Mol Biol2016; 164: 18–29.
26.
LaursenJHSondergaardHBAlbrechtsenAet al. Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis. Mult Scler2015; 21: 1414–1422.
27.
AgnelloLScazzoneCLo SassoBet al. VDBP, CYP27B1, and 25-hydroxyvitamin D gene polymorphism analyses in a group of Sicilian multiple sclerosis patients. Biochem Genet2017; 55: 183–192.
28.
AgliardiCGueriniFRZanzotteraMet al. Vitamin D-binding protein gene polymorphisms are not associated with MS risk in an Italian cohort. J Neuroimmunol2017; 305: 92–95.
29.
NiinoMKikuchiSFukazawaTet al. No association of vitamin D-binding protein gene polymorphisms in Japanese patients with MS. J Neuroimmunol2002; 127: 177–179.
30.
SimonKCMungerKLXingYet al. Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis. Mult Scler2010; 16: 133–138.
31.
OrtonSMRamagopalanSVParaAEet al. Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians. J Neurol Sci2011; 305: 116–120.
32.
HollsbergPHaahrSLarsenPMet al. MS and the group-specific component. Acta Neurol Scand1988; 78: 158–160.
33.
LindblomBWetterlingGLinkH.Distribution of group-specific component subtypes in multiple sclerosis. Acta Neurol Scand1988; 78: 443–444.
34.
Langer-GouldALucasRMXiangAHet al. Vitamin D-binding protein polymorphisms, 25-hydroxyvitamin D, sunshine and multiple sclerosis. Nutrients2018; 10: E184.
35.
MungerKLLevinLIHollisBWet al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA2006; 296: 2832–2838.
36.
Langer-GouldALucasRXiangAHet al. MS Sunshine study: Sun exposure but not vitamin D is associated with multiple sclerosis risk in Blacks and Hispanics. Nutrients2018; 10: E268.
37.
ThompsonAJBanwellBLBarkhofFet al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17: 162–173.
38.
QinZQinYLiuS.Alteration of DBP levels in CSF of patients with MS by proteomics analysis. Cell Mol Neurobiol2009; 29: 203–210.
39.
KroksveenACGuldbrandsenAVedelerCet al. Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls. Acta Neurol Scand Suppl2012; 195: 90–96.
40.
KulakowskaACiccarelliNJWenQet al. Hypogelsolinemia, a disorder of the extracellular actin scavenger system, in patients with multiple sclerosis. BMC Neurol2010; 10: 107.
41.
StoopMPSinghVDekkerLJet al. Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis. PLoS ONE2010; 5: e12442.
42.
OttervaldJFranzenBNilssonKet al. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. J Proteomics2010; 73: 1117–1132.
43.
LehmensiekVSussmuthSDTauscherGet al. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult Scler2007; 13: 840–849.
44.
ComabellaMFernandezMMartinRet al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain2010; 133: 1082–1093.
45.
PergaSGiuliano AlboALisKet al. Vitamin D binding protein isoforms and apolipoprotein E in cerebrospinal fluid as prognostic biomarkers of multiple sclerosis. PLoS ONE2015; 10: e0129291.
46.
GressnerOASchifflersMCKimPet al. Questioning the role of actinfree Gc-Globulin as actin scavenger in neurodegenerative central nervous system disease: Relationship to S-100B levels and blood-brain barrier function. Clin Chim Acta2009; 400: 86–90.
47.
HolmoyTMoenSMGundersenTAet al. 25-hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. Mult Scler2009; 15: 1280–1285.
48.
RithidechKNHonikelLMilazzoMet al. Protein expression profiles in pediatric multiple sclerosis: Potential biomarkers. Mult Scler2009; 15: 455–464.
49.
RinaldiAOSanseverinoIPurificatoCet al. Increased circulating levels of vitamin D binding protein in MS patients. Toxins2015; 7: 129–137.
50.
BehrensJRRascheLGiessRMet al. Low 25-hydroxyvitamin D, but not the bioavailable fraction of 25-hydroxyvitamin D, is a risk factor for multiple sclerosis. Eur J Neurol2016; 23: 62–67.
51.
SmoldersJPeelenEThewissenMet al. Circulating vitamin D binding protein levels are not associated with relapses or with vitamin D status in multiple sclerosis. Mult Scler2014; 20: 433–437.
52.
NiinoMSatoSFukazawaTet al. Decreased serum vitamin D levels in Japanese patients with multiple sclerosis. J Neuroimmunol2015; 279: 40–45.
53.
FioriniAKoudriavtsevaTBucajEet al. Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: The spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis. PLoS ONE2013; 8: e65184.
54.
NielsonCMJonesKSChunRFet al. Free 25-hydroxyvitamin D: Impact of vitamin D binding protein assays on racial-genotypic associations. J Clin Endocrinol Metab2016; 101: 2226–2234.
55.
NielsonCMJonesKSChunRFet al. Role of assay type in determining free 25-hydroxyvitamin D levels in diverse populations. N Engl J Med2016; 374: 1695–1696.
56.
HendersonCMLutseyPLMisialekJRet al. Measurement by a novel LC-MS/MS methodology reveals similar serum concentrations of vitamin D-binding protein in Blacks and Whites. Clin Chem2016; 62: 179–187.
57.
HoofnagleANEckfeldtJHLutseyPL.Vitamin D-binding protein concentrations quantified by mass spectrometry. N Engl J Med2015; 373: 1480–1482.
58.
DenburgMRHoofnagleANSayedSet al. Comparison of two ELISA methods and mass spectrometry for measurement of vitamin D-binding protein: Implications for the assessment of bioavailable vitamin D concentrations across genotypes. J Bone Miner Res2016; 31: 1128–1136.
59.
LublinFDReingoldSCCohenJAet al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology2014; 83: 278–286.
